Niagen Bioscience (NAGE) Profit After Tax (2010 - 2026)
Niagen Bioscience (NAGE) posted quarterly Profit After Tax of $6.3 million for Q1 2026, up 24.79% year-over-year from $5.1 million in Q1 2025, and up 54.78% quarter-over-quarter from $4.1 million in Q4 2025.
Powered by 
Analysis
Niagen Bioscience (NAGE) Profit After Tax (2010 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Profit After Tax for 17 consecutive years, with $6.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 24.79% year-over-year to $6.3 million; the TTM figure through Mar 2026 stood at $18.6 million (up 31.78% YoY), while the FY2025 annual figure was $17.4 million, up 103.3% from the prior year.
- Profit After Tax rose to $6.3 million in Q1 2026 per NAGE's latest filing, from $4.1 million in the prior quarter.
- Across five years, Profit After Tax topped out at $7.2 million in Q4 2024 and bottomed at -$7.7 million in Q1 2022.
- Historically, Profit After Tax has averaged $630705.9 across 5 years, with a median of -$15000.0 in 2024.
- On a YoY basis, Profit After Tax climbed as much as 24160.0% in 2025 and fell as far as 43.14% in 2025.
- Niagen Bioscience's Profit After Tax stood at -$1.4 million in 2022, then surged by 108.04% to $114000.0 in 2023, then soared by 6197.37% to $7.2 million in 2024, then tumbled by 43.14% to $4.1 million in 2025, then soared by 54.78% to $6.3 million in 2026.
- Business Quant data shows NAGE's Profit After Tax at $6.3 million in Q1 2026, $4.1 million in Q4 2025, and $4.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Niagen Bioscience | 251.05 Mn | 184.31 Mn | 19.31 Mn | 963,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 963,000.00 |
| Mar 31, 2026 | 6.32 Mn |
| Dec 31, 2025 | 4.08 Mn |
| Sep 30, 2025 | 4.58 Mn |
| Jun 30, 2025 | 3.61 Mn |
| Mar 31, 2025 | 5.06 Mn |
| Dec 31, 2024 | 7.18 Mn |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | -15,000.00 |
| Mar 31, 2024 | -492,000.00 |
| Dec 31, 2023 | 114,000.00 |
| Sep 30, 2023 | -959,000.00 |
| Jun 30, 2023 | -2.19 Mn |
| Mar 31, 2023 | -1.90 Mn |
| Dec 31, 2022 | -1.42 Mn |
| Sep 30, 2022 | -985,000.00 |
| Jun 30, 2022 | -6.40 Mn |
| Mar 31, 2022 | -7.74 Mn |
| Dec 31, 2021 | -5.33 Mn |
| Sep 30, 2021 | -8.86 Mn |